TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the …,

We hope these clinical trials can provide more effective treatment options for clinicians and benefit more ESCC patients.” “From Hodgkin’s lymphoma, …, We hope these clinical trials can provide more effective treatment options for clinicians and benefit more ESCC patients.” “From Hodgkin’s lymphoma, …, Read More

Scroll to Top